Latest Healthcare It News

Page 9 of 142
Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.
Ada Torres
Ada Torres
24 Sept 2026
Carlton Investments increased FY2026 profit and fully franked dividends, but its investment portfolio underperformed sharply as its largest holding, EVT, fell 22.6% in value. The company’s total portfolio return was negative 3.2%, compared with a 6.1% gain for the S&P/ASX 200 Accumulation Index.
Claire Turing
Claire Turing
24 Sept 2026
Vection Technologies has signed reciprocal five-year reseller agreements with Xerox, opening a potential Western European channel for its conversational AI, digital human, kiosk and XR technologies. The opportunity is strategically notable, but the agreements contain no minimum volumes, pricing or committed revenue.
Sophie Babbage
Sophie Babbage
24 Sept 2026
PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.
Victor Sage
Victor Sage
23 Sept 2026
Synertec has raised its FY27 revenue guidance by $8.0 million to $8.3 million, pointing to stronger contract conversion and visibility across its Engineering and Powerhouse businesses. The upgrade follows the $45.5 million ANSTO nuclear medicine manufacturing contract, but covers revenue only and not earnings or cash flow.
Victor Sage
Victor Sage
23 Sept 2026
Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.
Victor Sage
Victor Sage
22 Sept 2026
ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.
Victor Sage
Victor Sage
21 Sept 2026
Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.
Ada Torres
Ada Torres
21 Sept 2026
Austco Healthcare delivered record FY26 revenue and statutory profit, with stronger margins, cash generation and a modest recovery in contracted orders entering the new financial year. The company is pairing that momentum with further reseller consolidation, including the $2.88 million acquisition of Medical Communications Systems.
Victor Sage
Victor Sage
17 Sept 2026
Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.
Ada Torres
Ada Torres
16 Sept 2026
Paragon Care has lined up an on-market buy-back of up to 82.8 million shares, worth about $10.8 million at the latest closing price, while its employee trust can acquire a further 23.9 million shares. The transactions give the healthcare group two sizeable tools for managing its capital and incentive plans, although neither maximum is guaranteed to be completed.
Ada Torres
Ada Torres
16 Sept 2026
Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.
Victor Sage
Victor Sage
15 Sept 2026

Browse the archive

Full archive